Senti Biosciences Confirms Continuation of $6.0M At-The-Market Offering Under New Holding Company Structure
Summary
Senti Biosciences Holdings, Inc. confirms the continuation of its existing $17.5 million At-The-Market (ATM) offering, with approximately $6.0 million remaining available for sale, following its recent reorganization.
Key Events
-
ATM Program Assumed by Successor Entity
Senti Biosciences Holdings, Inc. has assumed the existing At-The-Market (ATM) equity offering program from its predecessor, Senti Biosciences, Inc., following a reorganization on April 24, 2026.
-
$6.0 Million Remaining in ATM Program
Approximately $6.0 million worth of common stock remains available for sale under the ATM program, which originally allowed for the sale of up to $17.5 million.
-
Ongoing Dilution Risk
The continuation of this ATM program, alongside a recently announced $40.0 million convertible note financing, signals a significant need for capital and potential for substantial shareholder dilution.
Analysis
This filing confirms that Senti Biosciences Holdings, Inc., as the successor registrant following a recent reorganization, has assumed the existing At-The-Market (ATM) equity offering program. Approximately $6.0 million remains available for sale under this program. This ongoing ATM program, combined with the recently announced $40.0 million convertible note financing, indicates a significant and multi-faceted capital raise strategy, which will likely result in substantial dilution for existing shareholders.
At the time of this filing, SNTI was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.8M. The 52-week trading range was $0.77 to $3.88. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.